Since
2020
The Netherlands
Diagnostics
TRL 3

Challenge

Currently, ELISA tests are the golden standard for biomolecule measurements. However, this platform needs centralised lab equipment and involves multiple steps, making these tests expensive and time consuming. Moreover, lack of point of care (PoC) testing options leads to delayed results, which in turn reduces actionability.

Opportunity

There are multiple applications where easy, fast and accurate biomolecule measurement would be beneficial. Examples of possible use cases are PoC infectious disease diagnostics and Therapeutic Drug Monitoring (TDM) for antibodies. Tests to measure biomolecules are not currently used very often because of the aforementioned shortcomings of ELISA tests and the lack of accuracy of existing PoC analysis methods.

Solution

Researchers from the Eindhoven University of Technology have developed a new, solution-based PoC platform using bioluminescent sensor proteins to detect biomolecules directly in blood plasma. The technology allows for automatic calibration and produces results with crude samples in a matter of minutes. The test and reader provide the same accuracy as ELISA but eliminate the need for time consuming (washing) steps whilst also offering cost savings.

Status

This patented platform is in the proof of concept phase. Next steps are to explore the most promising applications, decide on the first application, develop a medical device to be used for the clinical validation and commercialise the end product. The research team from Eindhoven is also, as we speak, looking into how this platform can help with the current COVID-19 crisis and future infectious outbreaks. This demonstrates the broad potential impact of this technology within the diagnostics and monitoring field.

Meet the team

Inventor - Maarten Merkx (2)

Maarten Merkx

Inventor

Roland 1 (3)

Roland Zegger

Venture Partner at NLC

Trained as a Pharmacist, he worked in several pharmaceutical companies and has broad experience in marketing and sales functions as well as general management.  As Venture Partner his focus is on building innovative companies and strengthening NLC’s abilities to bring innovations to healthcare.